中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

8 records (took 0.031 seconds)

    KOC1-DERIVED PEPTIDE AND VACCINE INCLUDING SAME
    1.
    发明申请
    KOC1-DERIVED PEPTIDE AND VACCINE INCLUDING SAME 审中-公开

    公开(公告)号：US20200155596A1

    公开(公告)日：2020-05-21

    申请号：US16773487

    申请日：2020-01-27

    Applicant: ONCOTHERAPY SCIENCE, INC.

    Inventor： Takuya TSUNODA ,  Ryuji OSAWA ,  Sachiko YAMASHITA ,  Tomohisa WATANABE ,  Tetsuro HIKICHI

    IPC: A61K35/14 ,  C12N15/09 ,  C12N5/10 ,  C07K7/08 ,  C07K7/06 ,  C07K16/18 ,  A61K48/00 ,  A61K39/00 ,  A61K35/12

    Abstract: The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

    HJURP PEPTIDES AND VACCINES INCLUDING THE SAME
    2.
    发明申请
    HJURP PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开

    公开(公告)号：US20160368958A1

    公开(公告)日：2016-12-22

    申请号：US15197278

    申请日：2016-06-29

    Applicant: OncoTherapy Science, Inc.

    Inventor： Yusuke NAKAMURA ,  Takuya TSUNODA ,  Ryuji OHSAWA ,  Sachiko YOSHIMURA ,  Tomohisa WATANABE

    IPC: C07K14/47 ,  C07K16/18

    CPC classification number: C07K14/4748 ,  A61K35/12 ,  A61K38/00 ,  A61K39/00 ,  C07K7/06 ,  C07K16/18

    Abstract: Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, Diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.

    TMEM22 PEPTIDES AND VACCINES INCLUDING THE SAME
    4.
    发明申请
    TMEM22 PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
    TMEM22肽和疫苗，包括它们

    公开(公告)号：US20140199336A1

    公开(公告)日：2014-07-17

    申请号：US14221721

    申请日：2014-03-21

    Applicant: ONCOTHERAPY SCIENCE, INC.

    Inventor： Yusuke NAKAMURA ,  Takuya TSUNODA ,  Ryuji OHSAWA ,  Sachiko YOSHIMURA ,  Tomohisa WATANABE

    IPC: C07K7/06

    CPC classification number: C07K7/06 ,  A61K39/00 ,  A61K39/0011 ,  A61K2039/57 ,  C07K14/705

    Abstract: Isolated peptides composed of the amino acid sequence of SEQ ID NO: 33 or fragments thereof that bind to HLA antigens and have cytotoxic T lymphocyte (CTL) inducibility and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical agents, substances and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors.

    Abstract translation: 描述了由SEQ ID NO：33的氨基酸序列组成的分离肽或其与HLA抗原结合并具有细胞毒性T淋巴细胞（CTL）诱导性的因此适合用于癌症免疫治疗，特别是癌症疫苗的上下文中的其片段 这里。 本发明进一步提供了肽，其包括前述肽或片段的一个，两个或几个氨基酸插入，取代或添加，但仍保留所需的细胞毒性T细胞诱导性。 还提供了编码任何上述肽的核酸以及包含上述肽或核酸中任何一种的药物，物质和组合物。 本发明的肽，核酸，药物，物质和组合物在癌症和肿瘤的治疗中具有特别的用途。

    KNTC2 PEPTIDES AND VACCINES CONTAINING THE SAME
    5.
    发明申请
    KNTC2 PEPTIDES AND VACCINES CONTAINING THE SAME 有权
    KNTC2肽及其含有的疫苗

    公开(公告)号：US20160008445A1

    公开(公告)日：2016-01-14

    申请号：US14772003

    申请日：2014-03-11

    Applicant: ONCOTHERAPY SCIENCE, INC.

    Inventor： Takuya TSUNODA ,  Ryuji OSAWA ,  Sachiko YOSHIMURA ,  Tomohisa WATANABE

    IPC: A61K39/00 ,  C07K16/18 ,  C07K7/06 ,  G01N33/574

    CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K2039/5154 ,  C07K7/06 ,  C07K14/47 ,  C07K16/18 ,  G01N33/505 ,  G01N33/57484

    Abstract: Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides derived from the KNTC2 gene that elicit CTLs and thus are suitable for use in the context of cancer immunotherapy are provided. The inventive peptides encompass both KNTC2-derived peptides and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding such peptides as well as pharmaceutical compositions that include any such peptides or polynucleotides as active agents. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of a metastatic- or post-operative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from KNTC2, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

    Abstract translation: 本文描述了针对癌症的肽疫苗。 特别地，提供了衍生自KNTC2基因的分离的表位肽，其引发CTL并因此适用于癌症免疫治疗的上下文中。 本发明的肽包括来自KNTC2的多肽及其修饰形式，其中一个，两个或几个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保持原始序列的必需的CTL诱导性。 还提供了编码这种肽的多核苷酸以及包括任何这样的肽或作为活性剂的多核苷酸的药物组合物。 还提供抗原呈递细胞和靶向这些肽的分离的CTL以及诱导抗原呈递细胞或CTL的方法。 此外，本发明提供了用于治疗和/或预防（即预防）癌症（肿瘤）和/或预防其转移或手术后复发的方法以及诱导CTL的方法，方法 用于诱导抗肿瘤免疫，使用衍生自KNTC2的肽，编码肽的多核苷酸或呈递肽的抗原呈递细胞，或本发明的药物组合物。

    HJURP PEPTIDES AND VACCINES INCLUDING THE SAME
    7.
    发明申请
    HJURP PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
    HJURP肽和疫苗，包括它们

    公开(公告)号：US20140256648A1

    公开(公告)日：2014-09-11

    申请号：US14205163

    申请日：2014-03-11

    Applicant: ONCOTHERAPY SCIENCE, INC.

    Inventor： Yusuke NAKAMURA ,  Takuya TSUNODA ,  Ryuji OHSAWA ,  Sachiko YOSHIMURA ,  Tomohisa WATANABE

    IPC: C07K7/06 ,  C07K16/18

    CPC classification number: C07K14/4748 ,  A61K35/12 ,  A61K38/00 ,  A61K39/00 ,  C07K7/06 ,  C07K16/18

    Abstract: Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in cancer immunotherapy are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, provided they retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding the peptides as well as pharmaceutical agents, substances and/or compositions that include any of the peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find utility in the treatment of cancers, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.

    Abstract translation: 本文描述了衍生自SEQ ID NO：50的分离的肽及其与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的片段，因此适用于癌症免疫治疗。 本发明的肽包括上述氨基酸序列及其修饰形式，只要它们保留原始序列所需的细胞毒性T细胞诱导能力即可。 还提供了编码肽的核酸以及包括任何肽或核酸的药剂，物质和/或组合物。 本发明的肽，核酸，药物，物质和组合物可用于治疗癌症，包括例如AML，膀胱癌，乳腺癌，宫颈癌，胆管细胞癌，CML，结肠直肠癌，食道癌， 扩散型胃癌，肝癌，NSCLC，淋巴瘤，骨肉瘤，卵巢癌，胰腺癌，前列腺癌，肾癌，SCLC，软组织肿瘤和睾丸肿瘤。

    C1ORF59 PEPTIDES AND VACCINES INCLUDING THE SAME
    8.
    发明申请
    C1ORF59 PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
    C1ORF59肽和疫苗，包括它们

    公开(公告)号：US20140199335A1

    公开(公告)日：2014-07-17

    申请号：US14199784

    申请日：2014-03-06

    Applicant: ONCOTHERAPY SCIENCE, INC.

    Inventor： Takuya TSUNODA ,  Ryuji OHSAWA ,  Sachiko YOSHIMURA ,  Tomohisa WATANABE

    IPC: C07K7/06

    CPC classification number: C07K7/06 ,  A61K39/00 ,  A61K39/0011 ,  C07K14/4748 ,  C12N2710/16222 ,  G01N33/57484 ,  G01N2333/47

    Abstract: The present invention provides isolated peptides having the amino acid sequence of SEQ ID NO: 43 or immunologically active fragments thereof, which bind to HLA antigen and have cytotoxic T lymphocyte (CTL) inducibility. The present invention further provides peptides which include one, two, or several amino acid insertions, substitution or addition to the aforementioned peptides or fragments, but still have the cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical agents and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents and compositions of this invention may be used for treating cancer or tumor.

    Abstract translation: 本发明提供具有与HLA抗原结合并具有细胞毒性T淋巴细胞（CTL）诱导能力的具有SEQ ID NO：43的氨基酸序列或其免疫活性片段的分离的肽。 本发明还提供了包括一个，两个或几个氨基酸插入，取代或加成上述肽或片段但仍具有细胞毒性T细胞诱导性的肽。 还提供了编码任何这些上述肽的核酸以及包含任何上述肽或核酸的药剂和组合物。 本发明的肽，核酸，药物和组合物可用于治疗癌症或肿瘤。

Patent Agency Ranking